American Conference Institute (ACI) will be holding its 14th Advanced Forum on Structuring, Negotiating, and Managing Life Sciences Collaborative Agreements and Acquisitions from February 16-17, 2011 in New York, NY. The conference will allow attendees to:
• Incorporate the right takeaways from recent deals into optimal business development strategies;
• Negotiate agreements that provide entry into key emerging markets;
• Anticipate when a partnership might lead to a full M&A and incorporate appropriate terms;
• Avoid traps that can undermine collaborative efforts and lead to alliance failures;
• Evaluate viable compensation structures;
• Minimize risks through more effective partner selection and due diligence;
• Structure option deals that meet both parties' potential objectives;
• Resolve hotly contested issues with universities; and
• Develop appropriate strategies for new technologies.
In particular, ACI's faculty will offer presentations on the following topics:
• Going beyond the basics to understand the driving forces and changing dynamics impacting the current deal-making landscape;
• Ensuring that increasing M&A is integrated into your business development strategy;
• Interactive discussion: Dos and don'ts for negotiating and drafting your next collaborative agreement;
• Spotlight industry remarks: "Building strategic partnerships as a core business strategy at Merck";
• Facilitating entry into emerging markets via strategic partnering;
• Why good deals go bad: Avoiding missteps in life sciences alliances;
• Negotiating options, staged acquisitions, hybrid transactions and straight-forward M&As;|• Entering into collaborative research agreements with academic institutions;
• Improving decision-making with practical methods for placing a value on products, patents, and licenses;
• Preparing for the exit: Drafting critical termination provisions;
• Case study: Analyzing a successful collaborative agreement; and
• Winning patent licensing strategies for the new biosimilars regime.
A post-conference workshop on "Life Sciences IP Due Diligence Boot Camp:Conducting Effective & Strategic Due Diligence for Life Science Partnering and M&A," will be offered February 18, 2011. In this workshop, ACI faculty will offer presentations on the following topics:
• Leading red flags that impact the value and success of a life sciences transaction;
• Factoring recent relevant IP case law and follow-on biologics legislation into your due diligence analysis;
• Creating a practical and useful checklist that incorporates both the business objectives of the deal and a comprehensive IP assessment;
• Evaluating the scope, breadth, validity and enforceability of the target's patents under evolving patent standards and regulatory protocols;
• Resolving ownership rights and inventorship issues arising under the target's prior contractual, third party and licensing obligations which could impact your deal; and
• Ensuring that the purchaser/licensee has the right to commercialize the IP at issue.
The agenda for the Pharma/Biotech Collaborative Agreements conference can be found here. A complete brochure for this conference, including an agenda, detailed descriptions of conference sessions, list of speakers, and registration form can be obtained here.
The registration fee for the conference is $2,295 (conference alone), $3,095 (conference and post-conference workshop), or $1,395 (post-conference workshop alone). Those registering by January 24, 2011 will receive a $200 discount. Those interested in registering for the conference can do so here, by calling 1-888-224-2480, or by faxing a registration form to 1-877-927-1563.
Patent Docs is a media partner of ACI's Life Sciences Collaborative Agreements and Acquisitions conference.
Comments